Skip to main content

Salivary lactoferrin is associated with cortical amyloid-beta load, cortical integrity, and memory in aging



Aging is associated with declining protective immunity and persistent low-grade inflammatory responses, which significantly contribute to Alzheimer’s disease (AD) pathogenesis. Detecting aging-related cerebral vulnerability associated with deterioration of the immune system requires from non-invasive biomarkers able to detect failures in the brain-immunity connection. Reduced levels of salivary lactoferrin (sLF), an iron-binding protein with immunomodulatory activity, have been related to AD diagnosis. However, it remains unknown whether decreased sLF is associated with increased cortical amyloid-beta (Aβ) load and/or with loss of cortical integrity in normal aging.


Seventy-four cognitively normal older adults (51 females) participated in the study. We applied multiple linear regression analyses to assess (i) whether sLF is associated with cortical Aβ load measured by 18F-Florbetaben (FBB)-positron emission tomography (PET), (ii) whether sLF-related variations in cortical thickness and cortical glucose metabolism depend on global Aβ burden, and (iii) whether such sLF-related cortical abnormalities moderate the relationship between sLF and cognition.


sLF was negatively associated with Aβ load in parieto-temporal regions. Moreover, sLF was related to thickening of the middle temporal cortex, increased FDG uptake in the posterior cingulate cortex, and poorer memory. These associations were stronger in individuals showing the highest Aβ burden.


sLF levels are sensitive to variations in cortical Aβ load, structural and metabolic cortical abnormalities, and subclinical memory impairment in asymptomatic older adults. These findings provide support for the use of sLF as a non-invasive biomarker of cerebral vulnerability in the general aging population.


Evidence suggests that aging modifies the composition of the oral microbiome favoring dysbiosis, increased infections, and persistent low-grade inflammation, which may ultimately compromise general health [1, 2]. Oral infections increase the morbidity and mortality risk in older individuals [3] and the susceptibility to develop systemic diseases, such as cardiovascular [4] and respiratory diseases [5], diabetes mellitus [6], rheumatoid arthritis [7], and dementia [8].

Lactoferrin (LF) is an iron-binding glycoprotein synthesized by neutrophil granulocytes and released by exocrine glands [9]. Among its multiple functions [10], LF contributes to host defense against infections by sequestering the ionic iron required for microbial growth [11,12,13,14]. In saliva, LF is modulated by the inflammatory state of the oral mucosa and plays a central role in regulating the oral microbiome [15].

LF has the capacity to penetrate into the brain parenchyma via receptor-mediated transcytosis [16,17,18]. Thus, exogenous administration of LF has been associated with improved spatial cognition through reductions in oxidative stress and inflammation in the hippocampus of aged mice [19], with reduced motor deficits in an induced mouse model of Parkinson disease (PD) [20, 21] and with decreased amyloid-beta (Aβ) aggregation and enhanced cognition in transgenic mouse models of Alzheimer’s disease (AD) [22, 23]. In humans, LF has been shown to accumulate in dopamine neurons of PD patients [24] and in cortical regions affected by AD pathology [25,26,27], likely to attenuate disease consequences. In line with this, LF administration in AD patients led to a reduction of AD pathology and improvement of cognitive performance [28].

Recent evidence suggests that salivary LF (sLF) could be an early, non-invasive, and cost-effective AD biomarker [29, 30]. In these studies, we showed that sLF levels are reduced in patients with mild cognitive impairment (MCI) and AD compared to healthy controls [29]. We next demonstrated that low concentrations of sLF were able to differentiate positive Aβ-MCI/AD patients not only from controls but also from patients with frontotemporal dementia [30]. However, it remains unknown whether sLF is related to cortical Aβ load in clinically normal older adults. This aspect deserves attention since Aβ depositions are ubiquitous in the brain of a high proportion of asymptomatic older individuals [31,32,33], and they are further considered an early pathological event in AD [34, 35]. To shed light into this, we evaluated associations between sLF and cortical Aβ burden measured with 18F-Florbetaben (FBB) amyloid positron emission tomography (PET) imaging. Our hypothesis is that reduced levels of sLF are related to increased Aβ load in clinically normal older adults, mainly in those cortical regions particularly vulnerable to accelerated aging and AD.

Regional patterns of cortical thinning and cortical hypometabolism are well-established signatures of prodromal and clinical AD [36,37,38,39]. However, patterns of cortical thickening and cortical hypermetabolism have also been associated with increased cerebral Aβ aggregates in asymptomatic older adults [40,41,42,43], likely signaling cerebral vulnerability and/or neural compensation in response to increased Aβ deposition. Based on these findings, we expect that sLF levels are negatively correlated with cortical thickness and cortical glucose metabolism in normal older individuals and that such relationships are stronger in those participants showing higher Aβ load. As previous studies have found associations between LF and improved memory [19, 44], we further predict that sLF-related variations in cortical thickness and/or FDG/FBB binding are associated with subclinical changes in memory function compared to other cognitive domains.



Seventy-four cognitively normal older adults participated in the study (age = 66.5 ± 5.7 years; 51 females). They were recruited from senior citizen’s associations, health-screening programs, and hospital outpatient services. All of them underwent neurological and neuropsychological assessment to discard the presence of early signs of dementia and objective cognitive impairment. Participants met the following inclusion criteria: (i) normal global cognitive status in the MMSE (scores ≥ 26), (ii) normal cognitive performance in the neuropsychological tests relative to appropriate reference values for age and education level, (iii) global score of 0 (no dementia) in the Clinical Dementia Rating (CDR), (iv) functional independence as assessed by the Spanish version of the Interview for Deterioration in Daily Living Activities [45], (v) scores ≤ 5 (no depression) in the short form of the Geriatric Depression Scale [46], and (vi) not be on medications that affect cognition. All participants gave informed consent to the experimental protocol approved by the Ethical Committee for Clinical Research of the Junta de Andalucía according to the principles outlined in the Declaration of Helsinki. Table 1 shows sample characteristics.

Table 1 Demographics and cognitive and cerebral Aβ measures

Neuropsychological assessment

The neuropsychological battery included different tests for assessment of memory, working memory, attention, executive function, and language. We computed a composite Z score for each cognitive domain comprising the following tests: (i) the Spanish version of the Memory Binding Test as an index of memory [47], (ii) the letter-number sequencing (Wechsler Adult Intelligence Scale-III) and the digit span (Wechsler Memory Scale-III) subtests as measures of working memory, (iii) the D2 test as an index of attention, (iv) the Trail Making test (TMT, forms A and B) and the Tower of London as measures of executive function, and (iv) the short form of the Boston Naming Test as a measure of language.

Quantification of sLF

Saliva samples were collected at 9:00–10:00 am in all subjects using the spitting method. Participants were asked to refrain from any oral stimulation (e.g., food, drink, smoke, chew gum, oral hygiene) or taking medication for at least 8 h prior to saliva collection. They were not allowed to wear lipstick or lip balm. The presence of blood contamination in saliva samples was excluded by visual inspection. Unstimulated whole saliva was collected into 50 ml conical sterile polypropylene tubes previously treated with 2% sodium azide solution. Samples were immediately placed on ice and centrifuged at 365g for 5 min at 4 °C. Supernatant saliva was then transferred into 1.5 ml polypropylene tubes, treated with a protease inhibitor cocktail (cOmplete Ultra Tablets mini, Roche, Basel, Switzerland), and stored at − 80 °C until analysis. Estimation of total protein concentration in saliva samples was performed with a bicinchoninic acid assay (BCA) (Pierce, Rockford, IL), according to the manufacturer’s instructions. We further correlated sLF with saliva protein levels to determine if salivary flow rate was associated with sLF concentration [48].

Levels of sLF were quantified using a commercially available ELISA kit (ab200015, Abcam, Cambridge, UK) according to manufacturer’s instructions. Briefly, we added 50 μL of saliva samples or standard to appropriate wells diluted 1:10,000 into sample diluent NS. All samples were tested in duplicate and the average of the two measurements (μg/ml) was used for statistical analyses. Mean intra- and inter-assay coefficients of variation (CV) were 4.6% and 8%, respectively. Intra-assay CV values were below 20% in all subjects (Fig. 1A).

Fig. 1

Effect of age and sex on sLF levels and global Aβ load. A Intra-assay coefficient of variation (CV) of sLF for each participant. B Relationship between salivary total protein content and sLF. C Relationship between age and sLF adjusted by sex. D sLF differences between sexes adjusted by age. E Association of age with global Aβ load (SUVR) adjusted by sex. F Sex differences in cortical Aβ load adjusted by age

MRI and PET acquisition

Structural brain images were acquired on a Philips Ingenia 3 T MRI scanner equipped with a 32-channel head coil (Philips, Best, Netherlands). A whole-brain T1-weighted magnetization prepared rapid gradient echo (MPRAGE) sequence was acquired in the sagittal plane using the following parameters: repetition time (TR) = 2600 ms, echo time (TE) = 4.7 ms, flip angle = 9°, matrix = 384 × 384, voxel resolution = 0.65 mm3 isotropic, and no gap between slices. Head motion was minimized by using a head restraint system and placing foam padding around the subject’s head. Participants were provided with headphones and foam earplugs to attenuate scanner noise.

PET examinations (2-[18F]fluoro-2-deoxy-D-glucose—FDG—and 18F-Florbetaben—FBB) were performed in a Philips Gemini 16 PET/CT scanner (Philips, Best, Netherlands). FDG-PET assessments were followed by FBB-PET scans two weeks later. Subjects fasted for at least 8 h before FDG-PET examination. Participants were injected with 185 MBq of FDG in a quiet, dimly lit room. FDG-PET images were acquired 30 min after injection with scan duration of 10 min. For FBB-PET imaging, participants were injected with 300 MBq of [18F] FBB (NeuraCeq™, Piramal Pharma) 90 min before acquisition. PET data were corrected for radioactive decay, dead time, attenuation, and scatter. Cerebral PET images were reconstructed iteratively with an isotropic voxel resolution of 2 mm3. Participants underwent a 20-min FBB-PET scan in dynamic mode consisting of 4 frames of 5 min each. Each frame was inspected for excessive motion. As no excessive head motion was detected in scanned images, the four frames were averaged to create a single static FBB brain image used for quantitative analysis. All FBB-PET scans were assessed visually by an expert in nuclear medicine and quantitatively using a standardized uptake value ratio (SUVR) cutoff of 1.43 [49].

Estimation of cortical thickness, FDG, and FBB binding

MRI data were processed using the analysis pipeline of Freesurfer v6.0 ( that involves intensity normalization, registration to Talairach, skull stripping, white matter (WM) segmentation, tessellation of WM boundaries, and automatic correction of topological defects [50]. Pial surface misplacements and erroneous WM segmentation were manually corrected on a slice-by-slice basis to enhance the reliability of cortical thickness measurements. Individual cortical thickness maps were smoothed using non-linear spherical wavelet-based de-noising schemes, which have previously shown greater specificity and sensitivity than Gaussian spatial filters for detecting local and global changes in cortical thickness [51]. Partial volume correction (PVC) of FDG/FBB PET images was performed with PetSurfer, a toolbox for PET analysis implemented in Freesurfer v6.0. We employed the Geometric Transfer Matrix-derived region-based voxel-wise method [52], assuming a uniform 6 mm point spread function. Cerebral FDG/FBB images were first co-registered to T1 scans. Next, PVC-cortical FDG/FBB images were transformed into SUVR using the pons or the grey matter of cerebellum as reference regions, respectively. Resulting PVC-FDG/FBB cortical-to-pons/cerebellum SUVR images were mapped into individual cortical surfaces and smoothed with non-linear spherical wavelet-based de-noising schemes [51]. Additionally, we obtained global cortical Aβ values for each participant using a FBB composite comprising 4 large bilateral cortical regions: frontal (orbitofrontal cortex/inferior frontal gyrus/middle frontal gyrus/superior frontal gyrus/frontal pole), cingulate (anterior/posterior/isthmus cingulate), parietal (precuneus/inferior parietal cortex/superior parietal cortex/supramarginal gyrus), and lateral temporal cortex (middle temporal/superior temporal gyri) [53].

Statistical analysis

Simple linear regression was used to estimate the relationship of sLF with total protein content in saliva samples, while multiple linear regression was used to determine the association of sLF and global Aβ load with age and sex. We also applied multiple-linear regression analysis to test the hypothesis that sLF levels are associated with between-individual variations in cortical thickness and cortical FDG/FBB binding in clinically normal older adults. Cerebral dependent variables were Box-Cox transformed to improve normality and alleviate heteroscedasticity [54]. All statistical models, except the one performed with FBB binding, were adjusted for global Aβ load, age, and sex. The model that included FBB binding as dependent variable was only adjusted by age and sex. To determine whether the association of sLF with either cortical thickness or FDG uptake was moderated by global Aβ load, we added the sLF × global Aβ load interaction as explanatory variable. The two interaction models were adjusted by age, sex, sLF, and global Aβ load.

Vertex-wise regression analyses with cortical thickness and FDG/FBB binding as dependent variables were performed using the SurfStat package ( Results were corrected for multiple comparisons using a previously validated hierarchical statistical model [55]. This procedure first controls the family-wise error rate in significant clusters over smoothed statistical maps applying random field theory; and it next controls the false discovery rate in vertices of significant clusters over unsmoothed statistical maps. The anatomical location of clusters that survived correction was identified by the location of each cluster’s peak vertex on the Desikan-Killiany atlas [56]. For each regression analysis, we reported the maximum F (i.e., Roy’s largest root) and its associated p value, which was obtained by comparing either the additive or interactive model with a model with no regressors (i.e., a model that only included the intercept). For each post-hoc contrast, we reported the maximum R2 and its associated p value for each significant cluster. After inferential evidence of a main effect, we computed the standardized measure of effect size (i.e., Cohen’s f2), which allows an evaluation of local effect size within the context of a multivariate regression model [57]. To establish the precision of effect sizes, we computed 95% confidence intervals (CI95%) using the normal approximated interval with bootstrapped bias and standard error (N = 10.000 bootstrap samples) through the function bootci implemented in Matlab.

We next assessed associations between levels of sLF and cognition. Five cognitive domains were assessed: memory, working memory, attention, language, and executive function. To improve normality and heteroscedasticity, the model included as dependent variable the Yeo-Johnson transformation of composite Z scores for each cognitive domain [58]. We applied linear mixed modeling as this approach allows for random intercepts across participants, which, in turn, reduces de variance of fixed effect estimates [59]. In particular, we specified a four-step mixed effects model. The main predictors were added in the first step (i.e., cognitive domain, sLF, sLF-related variations in cortical Aβ load, cortical thickness and cortical FDG uptake, age, and sex), whereas the two-, three-, and four-way interactions were sequentially added in subsequent steps. We next applied ANOVAs to compare the different models. These analyses were performed with R Statistical Software v3.0.1 (R Foundation for Statistical Computing, Vienna, Austria).

Power analysis

Power analysis was performed with the G*Power software (v3.1.9.6) ( We computed an a priori (prospective) power analysis (fixed model, R2 deviation from zero) to achieve a satisfactory power level of 80% given a α-level of 0.05 and a Cohen’s effect size (f) of 0.25. As sex was included as covariate of no interest, the number of predictors ranged between 6 and 10. Taking into account these parameters, a sample size between 62 and 74 participants was required to achieve the desired power.


Demographics, cognitive and cerebral Aβ measures

Table 1 includes demographics, cognitive and cerebral Aβ measures of the total sample and stratified by sex. The sample comprised 74 cognitively normal elderly subjects (51 females and 23 males). Ten of them showed a positive FBB scan (7 females and 3 males). sLF was not correlated with saliva protein levels (r = − 0.03, p = 0.8), arguing against an effect of salivary flow rate on sLF levels in our study (Fig. 1B). Regression analyses indicated that there was no main effect of age or sex on sLF (Fig. 1C, D) or global Aβ load (Fig. 1E, F). The age × sex interaction was also not significant for any of these dependent variables. On the contrary, we found a significant main effect of age on cognition, which was mostly evident for the memory domain, but found no significant differences between sexes or between cognitive domains (see Supplementary material).

Relationship between sLF and cortical Aβ load

Regression analysis revealed a main effect of sLF on cortical FBB binding after adjustment by age and sex (F3,70 = 8.3, p < 10−4). The post-hoc regression analysis showed a negative relationship between sLF levels and FBB binding in areas of the left temporal and inferior parietal lobe (\( {R}_{\mathrm{max}}^2 \) = 0.22, tmax = 4.50, pcluster = 0.006; f2 = 0.28, CI95%[0.21 0.35]). Results derived from this analysis are shown in Fig. 2A.

Fig. 2

Association of sLF with cortical Aβ load, cortical thickness and cortical FDG uptake. The t statistics projected into the inflated cortical surfaces indicate the negative associations of sLF with cortical Aβ load (A) after adjustment for age and sex and with cortical thickness (B) and cortical FDG uptake (C) after adjustment for age, sex, and global Aβ load. All cortical measurements were Box-Cox transformed before whole-cortex vertex-wise analysis. Color bar indicates the range of significant t values. Left (L) and right (R)

Relationship between sLF and cortical thickness/cortical FDG uptake

After adjustment by global Aβ load, age, and sex, we also found a main effect of sLF on cortical thickness (F4,69 = 11,52, p < 10−5) and FDG uptake (F4,69 = 11.2, p < 10−4). Post hoc regression analyses showed a negative association of sLF with cortical thickness in areas of the left middle temporal lobe (\( {R}_{\mathrm{max}}^2 \) = 0.19, tmax = 4.15, pcluster = 0.008; f2 = 0.32, CI95%[0.25 0.38]) and with FDG uptake in areas of the right posterior cingulate cortex (rPCC) (\( {R}_{\mathrm{max}}^2 \) = 0.2, tmax = 4.19, pcluster = 10−5; f2 = 0.55, CI95%[0.48 0.62]). Results from these analyses are illustrated in Fig. 2B, C.

Moderating role of global Aβ load on the relationship between sLF and cortical thickness/cortical FDG uptake

To assess the putative role of global Aβ load as a moderator of the relationship between sLF and cortical thickness, we built a new model including the sLF × global Aβ load interaction term. The ANOVA comparing the additive and interaction models showed significant differences over the rPCC (F5,68 = 9.35, p < 10−5, \( {R}_{\mathrm{max}}^2 \) = 0.32, tmax = 5.76, pcluster < 10−6; rho = 6.96, CI95%[3.8 10.1]). Figure 3A shows the results derived from this analysis on cortical surfaces and the scatter plot of the interaction effect. In particular, the correlation between sLF and cortical thickness was most negative for those individuals in the highest tertile of global Aβ load.

Fig. 3

Moderating role of global Aβ load on the association of sLF with cortical thickness or cortical FDG uptake. Whole-cortex vertex-wise assessment of the two-way sLF × global Aβ load interaction on either cortical thickness (A) or cortical FDG uptake (B). The left panel shows the t statistics projected into the inflated cortical surfaces. The right panel shows the scatter plots for the relationship between sLF and the mean of the Box-Cox transformed values of thickness or FDG uptake within the right posterior cingulate cortex in subjects in the lowest and highest tertile of global Aβ load adjusted by age, sex, sLF, and global Aβ load. Color bar indicates the range of significant t values. Right (R)

The interaction effect was also significant for the FDG uptake at the rPCC (F5,68 = 12.45, p < 10−4, \( {R}_{\mathrm{max}}^2 \) = 0.29, tmax = 5.39, pcluster = 0.002; rho = 6.65, CI95%[4.4 8.9]). As illustrated in Fig. 3B, individuals in the highest tertile of global Aβ load showed a more negative relationship between sLF and cortical FDG uptake compared to those in the lowest tertile.

Moderating role of sLF-related cortical variations on the association of sLF with cognition

We first built a mixed-effect model with cognition as dependent variable, with cognitive domain, sLF, age, sex, and sLF-related changes in Aβ load (i.e., the mean value of the significant Aβ cluster in Fig. 2A), cortical thickness (i.e., the mean value of the significant thickness cluster in Fig. 2B) and FDG uptake (i.e., the mean value of the significant FDG cluster in Fig. 2C) as fixed effects, and with participants as random effect. Results indicated that cognition was negatively associated with sLF (F1,74 = 10.4, p = 0.002), sLF-related changes in Aβ load (F1,74 = 4.3, p = 0.04), and age (F1,74 = 15.8, p = 0.0002).

Next, we built an interaction model with 4 two-way interactions terms (i.e., cognitive domain × sLF, sLF-related changes in Aβ load, cortical thickness and FDG uptake). This model provided a better fit to the data than the additive model (χ2 = 38, p = 0.001). The ANOVA revealed a significant association of cognitive domain with sLF (F4,296 = 7, p = 0.00002) and with sLF-related changes in Aβ load (F4,296 = 4.2, p = 0.002). Post hoc analyses indicated that both sLF and sLF-related changes in Aβ load were negatively associated with memory when compared with the remaining cognitive domains. These results are illustrated in Fig. 4A and Fig. 4B, respectively.

Fig. 4

Association of sLF and sLF-related changes in cortical Aβ load with scores in different cognitive domains. A Relationship of sLF with cognition as a function of the cognitive domain. B Association of sLF-related changes in Aβ load over left temporo-parietal (LTP) regions (see Fig. 2A) as a function of the cognitive domain. WM, working memory. SUVR, standardized uptake value ratio

We finally assessed whether these interactions were further moderated by sLF-related changes in either cortical thickness or cortical FDG uptake. But none of these models provided a better fit to the data when compared to the additive model or any of the interaction models mentioned above.


In this study, we showed that aging-related sLF is negatively associated with regional Aβ load, particularly in parieto-temporal regions of the left hemisphere. Results further revealed that global Aβ load moderated the association of sLF with increased thickness and FDG uptake in the rPCC. Remarkably, both sLF and sLF-related changes in Aβ load were associated with poorer memory. Together, these findings provide evidence supporting the role of sLF as a biomarker of cerebral vulnerability in normal aging and contribute to extend our understanding of sLF in the continuum aging-AD.

In consonance with previous results obtained in MCI and AD patients [29, 30], decreased levels of sLF were related to increased Aβ burden in left parieto-temporal regions of cognitively normal older adults. We have recently hypothesized that reduced sLF observed in prodromal and clinical stages of AD may indicate early immunological disturbances that eventually increase the risk of AD [60]. Low levels of sLF may assist oral dysbiosis, which, in turn, may produce long-term infections and a pro-inflammatory response that weakens the blood brain barrier, facilitating colonization of brain tissue by periodontal bacteria [61] and accelerating neuroinflammation that contribute to AD pathology [62]. In this vein, previous studies have shown an association between periodontal disease and brain Aβ accumulation in normal aging, suggesting that periodontal inflammation/infection may accelerate brain Aβ deposition [63, 64]. Our results complement these findings, suggesting that reductions of sLF relate to increased regional Aβ burden, which may reflect early immunological alterations potentially associated with higher risk of developing AD [60]. Alternatively, a recent study has shown that levels of LF in either saliva or cerebrospinal fluid (CSF) were not able to differentiate between controls, MCI/AD, and non-AD dementias. Nor did they find an association between sLF and CSF AD biomarkers [65]. These conflicting results do not invalidate our results that were obtained in cognitively normal elderly subjects, emphasizing the potential role of sLF to track cerebral Aβ changes in late life.

The present study further showed that between individual reductions in sLF are associated with thickening of the left middle temporal lobe and increased FDG uptake in the rPCC. Accumulated evidence suggests that cortical thickening of middle temporal regions occurs in cognitively normal elderly subjects before the onset of AD symptoms [42, 43, 66,67,68]. Accordingly, post mortem human brain studies have shown hypertrophy of neuronal cell bodies, nuclei, and nucleoli in asymptomatic individuals with Aβ aggregates, likely revealing a very early reaction to cerebral Aβ burden and/or the activation of cellular processes in an attempt to prevent the natural progression of AD [69]. Previous works have further identified a hypermetabolic phase in cognitively normal older adults, affecting the posterior cingulate among other cortical regions, which became hypometabolic in later stages of AD [70]. Patterns of increased cortical FDG uptake have also been observed in association with increased accumulation of Aβ deposition in asymptomatic older adults [40] that may result from Aβ-related microgliosis [71], overproduction of inflammatory mediators [72], and/or aberrant hyperactivation of cortical neurons instigated by Aβ burden [73]. Therefore, the link between decreased sLF and abnormal patterns of cortical thickness/cortical FGD uptake may mirror the earliest Aβ-related effects on vulnerable cortical regions in late life.

Interestingly, associations between decreased sLF and cortical thickening/cortical hypermetabolism were mostly evident in those individuals showing the highest global Aβ load. While it is increasingly clear that accumulation of Aβ plaques is not sufficient to cause AD [74], the mere presence of Aβ aggregates has adverse effects that might increase the risk for AD such as impaired microvascular integrity, unbalanced glucose homeostasis, failure in neuronal cell cycle control, and inflammatory responses regulated by microglia and astrocytes [75]. The moderating role of global Aβ burden on the relationship between sLF and cortical thickening/cortical hypermetabolism may reveal aggravated aging-related immunity deficits in individuals with the highest global Aβ concentration. Whether this association may eventually increase the likelihood of developing AD has to be determined in future studies. In the context of aging, substantial cerebral Aβ load could lead to chronic neuroinflammation favoring deregulation of the immune system and, consequently, altering the intrinsic immunomodulatory role of LF [76].

In line with this hypothesis, sLF-related increases in parieto-temporal Aβ load predicted lower cognition, particularly affecting memory. However, this relationship was not moderated by sLF-associated changes in either cortical thickness or FDG uptake. Previous studies have found greater LF deposition in brain regions enriched with Aβ plaques [25, 27], which may be interpreted as an attempt to minimize the consequences of cerebral amyloidosis. On the other hand, exogenous administration of LF has shown to stimulate the non-amyloidogenic processing of amyloid precursor protein and α-secretase activity, with a consequent reduction in Aβ deposition that ameliorates cognitive decline in mouse models of AD [22]. Beneficial effects of LF for the maintenance of cellular and tissue homeostasis may be due to an increase of autophagy activity via AMPK signaling through the LRP1 receptor [77].


The results of the current study are purely correlational, and we cannot infer any causal relationship between sLF, cerebral changes, and/or cognitive deficits. Furthermore, our findings were obtained with a relatively small sample and therefore they should be considered as preliminary and replicated in further experiments. Finally, additional studies should be carried out to determine if variations in sLF levels predict AD progression.


In summary, these findings provided first evidence relating sLF to regional Aβ load, cortical integrity, and poorer memory in clinically normal older adults. In particular, our results suggested that global Aβ load plays a major role in boosting associations between sLF and abnormal patterns of cortical thickness and cortical glucose metabolism, likely signaling early dysregulation of the immune system. Although these findings are preliminary, they represent a step further into the utilization of sLF as a non-invasive biomarker of cerebral vulnerability in the general aging population.

Availability of data and materials

The datasets employed in the current study are available from the corresponding author on reasonable request.





Alzheimer’s disease






Mild cognitive impairment


Mini Mental State Examination


Magnetic resonance imaging


Positron emission tomography


Positron emission tomography-computed tomography


Partial volume correction


Salivary lactoferrin


Standardized uptake value ratios


Trail making test


  1. 1.

    Garcia-Peña C, Alvarez-Cisneros T, Quiroz-Baez R, Friedland RP. Microbiota and aging. A review and commentary. Arch Med Res. 2017;48(8):681–9.

    Article  PubMed  Google Scholar 

  2. 2.

    Santoro A, Zhao J, Wu L, Carru C, Biagi E, Franceschi C. Microbiomes other than the gut: inflammaging and age-related diseases. Semin Immunopathol. 2020;42(5):589–605.

    Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Garcia RI, Krall EA, Vokonas PS. Periodontal disease and mortality from all causes in the VA Dental Longitudinal Study. Ann Periodontol. 1998;3(1):339–49.

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Beck JD, Slade G, Offenbacher S. Oral disease, cardiovascular disease and systemic inflammation. Periodontol 2000. 2000;23:110–20.

    CAS  Article  Google Scholar 

  5. 5.

    Scannapieco FA, Papandonatos GD, Dunford RG. Associations between oral conditions and respiratory disease in a national sample survey population. Ann Periodontol. 1998;3(1):251–6.

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Ritchie CS. Mechanistic links between type 2 diabetes and periodontitis. J Dent. 2009;37(8):S578–9.

    Article  PubMed  Google Scholar 

  7. 7.

    Bingham CO, Moni M. Periodontal disease and rheumatoid arthritis: the evidence accumulates for complex pathobiologic interactions. Curr Opin Rheumatol. 2013;25(3):345–53.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Ming Y, Hsu SW, Yen YY, Lan SJ. Association of oral health-related quality of life and Alzheimer disease: a systematic review. J Prosthet Dent. 2020;124(2):168–75.

    Article  PubMed  Google Scholar 

  9. 9.

    Metz-Boutigue MH, Jolles J, Mazurier J, Schoentgen F, Legrand D, Spik G, et al. Human lactotransferrin: amino acid sequence and structural comparison with the other transferrins. Eur J Biochem. 1984;145(3):659–76.

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Mayeur S, Spahis S, Pouliot Y, Levy E. Lactoferrin, a pleiotropic protein in health and disease. Antioxid Redox Signal. 2016;24(14):813–36.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Arnold RR, Cole MF, McGhee JR. A bactericidal effect for human lactoferrin. Science. 1977;197(4300):263–5.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Bullen JJ. The significance of iron in infection. Rev Infect Dis. 1981;3(6):1127–38.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Dominique L, Elizabeth E, Mathireu C, Joel M. Interactions of lactoferrin with cells involved in immune function. Biochem Cell Biol. 2006;84:282–90.

    Article  Google Scholar 

  14. 14.

    Drago-Serrano ME, Campos-Rodriguez R, Carrero JC, de la Garza M. Lactoferrin: balancing ups and downs of inflammation due to microbial infections. Int J Mol Sci. 2017;18(3):501.

    CAS  Article  PubMed Central  Google Scholar 

  15. 15.

    Conneely OM. Antiinflammatory activities of lactoferrin. J Am Coll Nutr. 2001;20(sup5):389S–95S.

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Kamemori N, Takeuchi T, Sugiyama A, Miyabayashi M, Kitagawa H, Shimizu H, et al. Trans-endothelial and trans-epithelial transfer of lactoferrin into the brain through BBB and BCSFB in adult rats. J Vet Med Sci. 2008;70(3):313–5.

    Article  PubMed  Google Scholar 

  17. 17.

    Hayashi T, To M, Saruta J, Sato C, Yamamoto Y, Kondo Y, et al. Salivary lactoferrin is transferred into the brain via the sublingual route. Biosci Biotechnol Biochem. 2017;81(7):1300–4.

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    Kopaeva Y, Cherepov AB, Zarayskaya IY, Nesterenko MV. Transport of human lactoferrin into mouse brain: administration routes and distribution. Bull Exp Biol Med. 2019;167(4):561–7.

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Zheng J, Xie Y, Li F, Zhou Y, Qi L, Liu L, et al. Lactoferrin improves cognitive function and attenuates brain senescence in aged mice. J Funct Foods. 2020;65:103736.

    CAS  Article  Google Scholar 

  20. 20.

    Xu SF, Zhang YH, Wang S, Pang ZQ, Fan YG, Li JY, et al. Lactoferrin ameliorates dopaminergic neurodegeneration and motor deficits in MPTP-treated mice. Redox Biol. 2019;21:101090.

    CAS  Article  Google Scholar 

  21. 21.

    Liu H, Wu H, Zhu N, Xu Z, Wang Y, Qu Y, et al. Lactoferrin protects against iron dysregulation, oxidative stress, and apoptosis in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson’s disease in mice. J Neurochem. 2020;152(3):397–415.

    CAS  Article  PubMed  Google Scholar 

  22. 22.

    Guo C, Yang ZH, Zhang S, Chai R, Xue H, Zhang YH, et al. Intranasal lactoferrin enhances α-secretase-dependent amyloid precursor protein processing via the ERK1/2-CREB and HIF-1α pathways in an Alzheimer’s disease mouse model. Neuropsychopharmacology. 2017;42(13):2504–15.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  23. 23.

    Abdelhamid M, Jung CG, Zhou C, Abdullah M, Nakano M, Wakabayashi H, et al. Dietary lactoferrin supplementation prevents memory impairment and reduces amyloid-β generation in J20 mice. J Alzheimers Dis. 2020;74(1):245–59.

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    Rousseau E, Michel PP, Hirsch EC. The iron-binding protein lactoferrin protects vulnerable dopamine neurons from degeneration by preserving mitochondrial calcium homeostasis. Mol Pharmacol. 2013;84(6):888–98.

    CAS  Article  PubMed  Google Scholar 

  25. 25.

    Kawamata T, Tooyama I, Yamada T, Walker DG, McGeer PL. Lactotransferrin immunocytochemistry in Alzheimer and normal human brain. Am J Pathol. 1993;142(5):1574–85.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Leveugle B, Spik G, Perl DP, Bouras C, Fillit HM, Hof PR. The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis. Brain Res. 1994;650(1):20–31.

    CAS  Article  PubMed  Google Scholar 

  27. 27.

    Wang L, Sato H, Zhao S, Tooyama I. Deposition of lactoferrin in fibrillar-type senile plaques in the brains of transgenic mouse models of Alzheimer’s disease. Neurosci Lett. 2010;481(3):164–7.

    CAS  Article  PubMed  Google Scholar 

  28. 28.

    Mohamed WA, Salama RM, Schaalan MF. A pilot study on the effect of lactoferrin on Alzheimer’s disease pathological sequelae: Impact of the p-Akt/PTEN pathway. Biomed Pharmacother. 2019;111:714–23.

    CAS  Article  PubMed  Google Scholar 

  29. 29.

    Carro E, Bartolome F, Bermejo-Pareja F, Villarejo-Galende A, Molina JA, Ortiz P, et al. Early diagnosis of mild cognitive impairment and Alzheimer’s disease based on salivary lactoferrin. Alzheimers Dement (Amst). 2017;8:131–8.

    Article  Google Scholar 

  30. 30.

    Gonzalez-Sanchez M, Bartolome F, Antequera D, Puertas-Martin V, Gonzalez P, Gomez-Grande A, et al. Decreased salivary lactoferrin levels are specific to Alzheimer’s disease. EBioMedicine. 2020;57:102834.

    Article  PubMed  PubMed Central  Google Scholar 

  31. 31.

    Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003;62(11):1087–95.

    CAS  Article  PubMed  Google Scholar 

  32. 32.

    Dugger BN, Hentz JG, Adler CH, Sabbagh MN, Shill HA, Jacobson S, et al. Clinicopathological outcomes of prospectively followed normal elderly brain bank volunteers. J Neuropathol Exp Neurol. 2014;73(3):244–52.

    Article  PubMed  Google Scholar 

  33. 33.

    Gordon BA, Blazey T, Su Y, Fagan AM, Holtzman DM, Morris JC, et al. Longitudinal β-amyloid deposition and hippocampal volume in preclinical Alzheimer disease and suspected non-Alzheimer disease pathophysiology. JAMA Neurol. 2016;73(10):1192–200.

    Article  PubMed  PubMed Central  Google Scholar 

  34. 34.

    Jack CR Jr, Wiste HJ, Weigand SD, Rocca WA, Knopman DS, Mielke MM, et al. Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol. 2014;13(10):997–1005.

    Article  PubMed  PubMed Central  Google Scholar 

  35. 35.

    Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924–38.

    Article  PubMed  PubMed Central  Google Scholar 

  36. 36.

    Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003;30(8):1104–13.

    Article  PubMed  Google Scholar 

  37. 37.

    Singh V, Chertkow H, Lerch JP, Evans AC, Dorr AE, Kabani NJ. Spatial patterns of cortical thinning in mild cognitive impairment and Alzheimer’s disease. Brain. 2006;129(11):2885–93.

    Article  PubMed  Google Scholar 

  38. 38.

    Dickerson BC, Bakkour A, Salat DH, Feczko E, Pacheco J, Greve DN, et al. The cortical signature of Alzheimer’s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19(3):497–510.

    Article  PubMed  Google Scholar 

  39. 39.

    Mosconi L, Mistur R, Switalski R, Tsui WH, Glodzik L, Li Y, et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2009;36(5):811–22.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  40. 40.

    Oh H, Habeck C, Madison C, Jagust W. Covarying alterations in Aβ deposition, glucose metabolism, and gray matter volume in cognitively normal elderly. Hum Brain Mapp. 2014;35(1):297–308.

    Article  PubMed  Google Scholar 

  41. 41.

    Yi D, Lee DY, Sohn BK, Choe YM, Seo EH, Byun MS, et al. Beta-amyloid associated differential effects of APOE ε4 on brain metabolism in cognitively normal elderly. Am J Geriatr Psychiatry. 2014;22(10):961–70.

    Article  PubMed  Google Scholar 

  42. 42.

    Cantero JL, Atienza M, Sanchez-Juan P, Rodriguez-Rodriguez E, Vazquez-Higuera JL, Pozueta A, et al. Cerebral changes and disrupted gray matter cortical networks in asymptomatic older adults at risk for Alzheimer’s disease. Neurobiol Aging. 2018;64:58–67.

    CAS  Article  PubMed  Google Scholar 

  43. 43.

    Cantero JL, Atienza M, Lage C, Zaborszky L, Vilaplana E, Lopez-Garcia S, et al. Atrophy of basal forebrain initiates with tau pathology in individuals at risk for Alzheimer’s disease. Cereb Cortex. 2020;30(4):2083–98.

    Article  PubMed  Google Scholar 

  44. 44.

    Madi NM, El-Saka MH. The possible protective effect of lactoferrin on lipopolysaccharide-induced memory impairment in albino rats. Alexandria J Med. 2018;54(4):295–8.

    Article  Google Scholar 

  45. 45.

    Böhm P, Peña-Casanova J, Aguilar M, Hernandez G, Sol JM, Blesa R. Clinical validity and utility of the interview for deterioration of daily living in dementia for Spanish-speaking communities. Int Psychogeriatr. 1998;10(3):261–70.

    Article  PubMed  Google Scholar 

  46. 46.

    Sheikh JL, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. Clin Gerontol. 1986;5:165–73.

    Article  Google Scholar 

  47. 47.

    Gramunt N, Sanchez-Benavides G, Buschke H, Dieguez-Vide F, Peña-Casanova J, Masramon X, et al. The memory binding test: Development of two alternate forms into Spanish and Catalan. J Alzheimers Dis. 2016;52(1):283–93.

    Article  PubMed  Google Scholar 

  48. 48.

    Corey-Bloom J, Haque AS, Park S, Nathan AS, Baker RW, Thomas EA. Salivary levels of total huntingtin are elevated in Huntington’s disease patients. Sci Rep. 2018;8(1):7371.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  49. 49.

    Bullich S, Seibyl J, Catafau AM, Jovalekic A, Koglin N, Barthel H, et al. Optimized classification of 18F-Florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment. Neuroimage Clin. 2017;15:325–32.

    Article  PubMed  PubMed Central  Google Scholar 

  50. 50.

    Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci USA. 2000;97(20):11050–5.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  51. 51.

    Bernal-Rusiel JL, Atienza M, Cantero JL. Detection of focal changes in human cortical thickness: spherical wavelets versus Gaussian smoothing. Neuroimage. 2008;41(4):1278–92.

    Article  PubMed  Google Scholar 

  52. 52.

    Greve DN, Salat DH, Bowen SL, Izquierdo-Garcia D, Schultz AP, Catana C, et al. Different partial volume correction methods lead to different conclusions: an 18 F-FDG-PET study of aging. Neuroimage. 2016;132:334–43.

    Article  PubMed  Google Scholar 

  53. 53.

    Mormino EC, Betensky RA, Hedden T, Schultz AP, Ward A, Huijbers W, et al. Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82(20):1760–7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  54. 54.

    Box GEP, Cox DR. An analysis of transformations. J R Stat Soc Ser B. 1964;26:211–52.

    Google Scholar 

  55. 55.

    Bernal-Rusiel JL, Atienza M, Cantero JL. Determining the optimal level of smoothing in cortical thickness analysis: a hierarchical approach based on sequential statistical thresholding. Neuroimage. 2010;52(1):158–71.

    Article  PubMed  Google Scholar 

  56. 56.

    Desikan RS, Segonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31(3):968–80.

    Article  PubMed  Google Scholar 

  57. 57.

    Cohen JE. Statistical power analysis for the behavioral sciences. Hillsdale: Lawrence Erlbaum Associates, Inc; 1988.

    Google Scholar 

  58. 58.

    Yeo IK, Johnson RA. A new family of power transformations to improve normality or symmetry. Biometrika. 2000;87(4):954–9.

    Article  Google Scholar 

  59. 59.

    Clark TS, Linzer DA. Should I use fixed or random effects? Pol Sci Res Meth. 2015;3:399–408.

    Google Scholar 

  60. 60.

    Bermejo-Pareja F, Del Ser T, Valenti M, de la Fuente M, Bartolome F, Carro E. Salivary lactoferrin as biomarker for Alzheimer’s disease: brain-immunity interactions. Alzheimers Dement. 2020;16(8):1196–204.

    Article  PubMed  PubMed Central  Google Scholar 

  61. 61.

    Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-brain barrier: from physiology to disease and back. Physiol Rev. 2019;99(1):21–78.

    CAS  Article  PubMed  Google Scholar 

  62. 62.

    Kamer AR, Dasanayake AP, Craig RG, Glodzik-Sobanska L, Bry M, de Leon MJ. Alzheimer’s disease and peripheral infections: the possible contribution from periodontal infections, model and hypothesis. J Alzheimers Dis. 2008;13(4):437–49.

    CAS  Article  PubMed  Google Scholar 

  63. 63.

    Kamer AR, Pirraglia E, Tsui W, Rusinek H, Vallabhajosula S, Mosconi L, et al. Periodontal disease associates with higher brain amyloid load in normal elderly. Neurobiol Aging. 2015;36(2):627–33.

    CAS  Article  PubMed  Google Scholar 

  64. 64.

    Kamer AR, Pushalkar S, Gulivindala D, Butler T, Li Y, Annam KRC, et al. Periodontal dysbiosis associates with reduced CSF Aβ42 in cognitively normal elderly. Alzheimers Dement (Amst). 2021;13:e12172.

    Google Scholar 

  65. 65.

    Gleerup HS, Jensen CS, Høgh P, Hasselbalch SG, Simonsen AH. Lactoferrin in cerebrospinal fluid and saliva is not a diagnostic biomarker for Alzheimer's disease in a mixed memory clinic population. EBioMedicine. 2021;67:103361.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  66. 66.

    Chetelat G, Villemagne VL, Pike KE, Baron JC, Bourgeat P, Jones G, et al. Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain. 2010;133(11):3349–58.

    Article  PubMed  Google Scholar 

  67. 67.

    Fortea J, Sala-Llonch R, Bartres-Faz D, Llado A, Sole-Padulles C, Bosch B, et al. Cognitively preserved subjects with transitional cerebrospinal fluid ß-amyloid 1-42 values have thicker cortex in Alzheimer’s disease vulnerable areas. Biol Psychiatry. 2011;70(2):183–90.

    CAS  Article  PubMed  Google Scholar 

  68. 68.

    Johnson SC, Christian BT, Okonkwo OC, Oh JM, Harding S, Xu G, et al. Amyloid burden and neural function in people at risk for Alzheimer’s Disease. Neurobiol Aging. 2014;35(3):576–84.

    CAS  Article  PubMed  Google Scholar 

  69. 69.

    Iacono D, O’Brien R, Resnick SM, Zonderman AB, Pletnikova O, Rudow G, et al. Neuronal hypertrophy in asymptomatic Alzheimer disease. J Neuropathol Exp Neurol. 2008;67(6):578–89.

    Article  PubMed  Google Scholar 

  70. 70.

    Benzinger TL, Blazey T, Jack CR Jr, Koeppe RA, Su Y, Xiong C, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease. Proc Natl Acad Sci USA. 2013;110(47):E4502–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  71. 71.

    Fellin T, Pascual O, Gobbo S, Pozzan T, Haydon PG, Carmignoto G. Neuronal synchrony mediated by astrocytic glutamate through activation of extrasynaptic NMDA receptors. Neuron. 2004;43(5):729–43.

    CAS  Article  PubMed  Google Scholar 

  72. 72.

    Vezzani A, Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia. 2005;46(11):1724–43.

    CAS  Article  PubMed  Google Scholar 

  73. 73.

    Palop JJ, Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neural networks. Nat Neurosci. 2010;13(7):812–8.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  74. 74.

    Drachman DA. The amyloid hypothesis, time to move on: amyloid is the downstream result, not cause, of Alzheimer’s disease. Alzheimers Dement. 2014;10(3):372–80.

    Article  PubMed  Google Scholar 

  75. 75.

    Herrup K. The case for rejecting the amyloid cascade hypothesis. Nat Neurosci. 2015;18(6):794–9.

    CAS  Article  PubMed  Google Scholar 

  76. 76.

    Actor JK, Hwang SA, Kruzel ML. Lactoferrin as a natural immune modulator. Curr Pharm Des. 2009;15(17):1956–73.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  77. 77.

    Aizawa S, Hoki M, Yamamuro Y. Lactoferrin promotes autophagy via AMP-activated protein kinase activation through low-density lipoprotein receptor-related protein 1. Biochem Biophys Res Commun. 2017;493(1):509–13.

    CAS  Article  PubMed  Google Scholar 

Download references


Not applicable.


This work was supported by research grants from the Spanish Ministry of Economy and Competitiveness (PID2020-119978RB-I00 to JLC, PSI2017-85311-P and PID2020-118825GB-I00 to MA), Junta de Andalucía (PY20_00858 to JLC) Research Program for a Long-Life Society (grant number 0551_PSL_6_E to JLC), and CIBERNED (CB06/05/1111 to JLC).

Author information




JLC conceived the study and wrote the manuscript. JLC, MA, MFA, and LR contributed to the data acquisition, data analysis, and preparation of figures. EC performed lactoferrin determinations. All authors read and approved the final version of the manuscript.

Corresponding author

Correspondence to Jose L. Cantero.

Ethics declarations

Ethics approval and consent to participate

All participants gave informed consent to the experimental protocol approved by the Ethical Committee for Clinical Research of the Junta de Andalucía according to the principles outlined in the Declaration of Helsinki.

Consent for publication

Not applicable.

Competing interests

Dr. Carro is co-founder of GEROA Diagnostics.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Reseco, L., Atienza, M., Fernandez-Alvarez, M. et al. Salivary lactoferrin is associated with cortical amyloid-beta load, cortical integrity, and memory in aging. Alz Res Therapy 13, 150 (2021).

Download citation


  • Saliva
  • Lactoferrin
  • Aging
  • Amyloid-beta PET
  • Cortical thickness